Clenbuterol toxicity: A NSW Poisons Information Centre experience

Medical Journal of Australia

Volumn 200, Issue 4, 2014, Pages 219-221

  Brett, Jonathan ^a   Dawson, Andrew H ^b   Brown, Jared A ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLENBUTEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CASE REPORT; CHILD; FEMALE; HUMAN; INFANT; INTOXICATION; MALE; MIDDLE AGED; POISON CENTER; PRESCHOOL CHILD; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANABOLIC AGENTS; ANTI-OBESITY AGENTS; AUSTRALIAN CAPITAL TERRITORY; CHILD; CHILD, PRESCHOOL; CLENBUTEROL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; NEW SOUTH WALES; POISON CONTROL CENTERS; POISONING; RETROSPECTIVE STUDIES; TASMANIA; YOUNG ADULT;

EID: 84899143971     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.10982     Document Type: Article

References (17)

1. Couet W, Girault J, Reigner BG, et al. Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation. Int J Clin Pharmacol Ther Toxicol 1989; 27: 467-472.
2. ComLaw. Poisons Standard 2012-F2012L01200. Schedule 1-Standard for the Uniform Scheduling of Medicines and Poisons No. 3. Commonwealth of Australia, 2012. http:// www.comlaw.gov.au/Details/F2012L01200 (accessed Aug 2013).
3. Mitchell GA, Dunnavan G. Illegal use of betaadrenergic agonists in the United States. J Anim Sci 1998; 76: 208-211.
4. Barbosa J, Cruz C, Martins J, et al. Food poisoning by clenbuterol in Portugal. Food Addit Contam 2005; 22: 563-566.
5. Salleras L, Dominguez A, Mata E, et al. Epidemiologic study of an outbreak of clenbuterol poisoning in Catalonia, Spain. Public Health Rep 1995; 110: 338-342.
6. Kuiper HA, Noordam MY, van Dooren-Flipsen MM, et al. Illegal use of beta-adrenergic agonists: European Community. J Anim Sci 1998; 76: 195-207.
7. Hoffman RS, Kirrane BM, Marcus SM; Clembuterol Study Investigators. A descriptive study of an outbreak of clenbuterol-containing heroin. Ann Emerg Med 2008; 52: 548-553.
8. Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol 2007; 3: 56-60.
9. Kierzkowska B, Stańczyk J, Kasprzak JD. Myocardial infarction in a 17-year-old body builder using clenbuterol. Circ J 2005; 69: 1144-1146.
10. Goldstein DR, Dobbs T, Krull B, Plumb VJ. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J 1998; 91: 780-784.
11. Schechter E, Hoffman RS, Stajic M, et al. Pulmonary edema and respiratory failure associated with clenbuterol exposure. Am J Emerg Med 2007; 25: 735. e1-e3.
12. Chan TY. Health hazards due to clenbuterol residues in food. J Toxicol Clin Toxicol 1999; 37: 517-519.
13. World Anti-Doping Agency. WADA statement on clenbuterol 2011. http://www.wada-ama.org/en/ media-center/archives/articles/wadastatement-on-clenbuterol (accessed Jun 2013).
14. Spiller HA, James KJ, Scholzen S, Borys DJ. A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst Abus 2013; 34: 306-312.
15. Guest K. Clenbuterol: the new weight loss wonder drug gripping planet zero. The Independent 2014; 4. Feb. http://www.independent.co.uk/life-style/ health-and-families/health-news/clenbuterolthe-new-weightloss-wonder-drug-grippingplanet-zero-441059.html (accessed Feb 2014).
16. Pulce C, Saviuc P, Pineau X, et al. Clenbuterol: retrospective study of cases from the French poison and toxicovigilance centres between 2000 and 2008 [abstract]. Clin Toxicol 2011; 49: 215.
17. Lust EB, Barthold C, Wichman TO, et al. Human health hazards of veterinary medications: information for emergency departments. J Emerg Med 2011; 40: 198-207.